Bladder Cancer Clinical Trial
Official title:
A Phase I Clinical Trial Assessing Intravesical Antisense Oligonucleotide Targeting Heat Shock Protein 27 for the Treatment of Superficial Bladder Cancer
NCT number | NCT00959868 |
Other study ID # | BL-01 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 1 |
First received | August 13, 2009 |
Last updated | February 10, 2012 |
Start date | July 2009 |
This is a single centre, open label, phase I dose escalation trial using a modified
accelerated titration design. Patients with superficial bladder tumour (Ta or T1) or CIS and
candidates for transurethral resection or muscle invasive disease (>T2) and candidates for
radical cystectomy will be enrolled.
OGX-427 will be given neoadjuvantly over 8 days, followed by a transurethral resection (for
superficial disease) or radical cystectomy (for muscle invasive disease).
Baseline Hsp27 levels will be determined from pre-treatment cytological samples from bladder
washings and tumour biopsies performed prior to therapy.
Post-treatment PK and PD data will be determined from TUR (for Ta, T1 tumours) or radical
cystectomy (for T2 tumours) specimens. A recommended phase II dose will be determined from
the toxicity, tissue pK, and percentage of Hsp27 knockdown. Effects of treatment on Hsp27
client protein levels and apoptotic index will also be evaluated.
Evaluation during protocol treatment will take place to assess toxicity. Assessments will
occur on various visits as per Evaluation Schedule. Adverse event evaluation based on NCI
CTCAEv3.0. For quality of life assessment during treatment, the EORTC QLC-BLS24 will be used
before first treatment (day 1) and prior to surgery (TURBT or radical cystectomy). The Day 1
QOL assessment will serve as baseline.
After removal from protocol treatment, all subjects will be followed for toxicity related to
study drug for 30 days.
After the study, subjects will be followed according to standard of care. Follow-up for
tumour recurrence or superficial tumours will be assessed every three months by cystoscopic
examination for two years, then every six months for the next two years, and then yearly
thereafter.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patient age must be > 18 2. Histologic evidence of bladder cancer (superficial or muscle invasive) or CIS as evidenced by: - Patients presenting with superficial tumours and unknown pathological stage will have in-clinic bladder washings (performed cystoscopically) and biopsy (cup biopsy). - Patients with recurrent superficial disease (Ta or T1) and tissue that is available for baseline studies (i.e. tissue from previous transurethral resection stored in paraffin blocks) will be eligible for trial without requiring cytology or biopsy. - Patients with previously diagnosed T1 tumours and requiring re-resection of bladder tumour will be eligible if tissue from the original TURBT is available for baseline studies. - Patients presenting as muscle invasive (>T2) disease will be eligible if they are candidates for radical cystectomy and if baseline tissue from initial resections is available for baseline studies 3. No intravesical therapies within the previous 6 months 4. No evidence of metastatic disease as determined by physical exam, CT scan or chest- x-ray, where indicated. 5. ECOG status must be 0, 1, or 2 6. Laboratory requirements (within 7 days of treatment): - negative urine cultures - Absolute neutrophils count> 1.5 x 109 cells/L, and platelets count> 100 x 109/L, - Total bilirubin < 1.5 x upper normal limit (ULN), AST and/or ALT < 1.5 x ULN, alkaline phosphatase < 1.5 x ULN, and serum creatinine < 1.5 x ULN. - PTT and INR, within normal limits 7. Patient must be able to complete the quality of life questionnaires in either English or French 8. Patients must provide written informed consent. Exclusion Criteria: 1. Patients with "indeterminate" or "negative" results from biopsy or cytology will be ineligible for the trial. 2. Patients taking warfarin or Coumadin anticoagulation therapy or who have a bleeding disorder. NOTE: Patients who require anticoagulation therapy while on study will be removed from study treatment. 3. Pregnant or lactating women 4. Patients not accessible for follow-up 5. Patients with an active urinary tract infection, upper tract urothelial tumors, active infection including tuberculosis, concurrent febrile illness or impaired immune response from any cause 6. Patients with contraindication to spinal or general anesthesia required for a transurethral resection or radical cystectomy 7. Recent (<14 days) urethral trauma or inability to perform catheterization or cystoscopy safely 8. Patients known to have a serious illness or medical condition that would impair protocol treatment delivery. |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | The Prostate Centre at Vancouver General Hospital | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
Vancouver Coastal Health | Canadian Cancer Trials Group, Vancouver General Hospital Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To define the maximum tolerated dose (MTD) of OGX-427 administered as an intravesical instillation. | The study medication will be escalated according to a fixed dose escalation plan. Three subjects will be treated per cohort. If one of the three subjects experiences a DLT, three additional subjects will be treated at that dose level (i.e. maximum of 6 subjects per cohort) | One year | Yes |
Primary | To define the dose-limiting toxicities (DLTs) of OGX-427 administered as an intravesical instillation. | The study medication will be escalated according to a fixed dose escalation plan. Three subjects will be treated per cohort. If one of the three subjects experiences a DLT, three additional subjects will be treated at that dose level(i.e. maximum of 6 subjects per cohort) | one year | Yes |
Secondary | To determine the toxicity profile of OGX-427 when administered intravesically. | One year | No | |
Secondary | To measure evidence of OGX-427 effect on expression of Hsp27. | one year | No | |
Secondary | To determine the bladder PK and PD profile of OGX-427 after intravesical administration. | one year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |